Dalbavancin Hydrochloride is Used for treating acute bacterial skin and skin structure infections (ABSSSI) in both adults and pediatric patients. It was first introduced by Abbvie Inc in its drug Dalvance on May 23, 2014.

Dalbavancin Hydrochloride Patents

Given below is the list of patents protecting Dalbavancin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Dalvance	US6900175	Methods of administering dalbavancin for treatment of bacterial infections	May 23, 2028	Abbvie
Dalvance	US7115564	Stable pharmaceutical compositions of dalbavancin and methods of administration	Nov 14, 2023 (Expired)	Abbvie
Dalvance	US7119061	Dalbavancin compositions for treatment of bacterial infections	Nov 14, 2023 (Expired)	Abbvie
Dalvance	US8143212	Dalbavancin compositions for treatment of bacterial infections	Nov 14, 2023 (Expired)	Abbvie

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳